September 2008
Worldwide Biotech;Sep2008, Vol. 20 Issue 9, p2
Trade Publication
The article reports on the extension of the European licensing agreement between Swedish pharmaceutical company Orexo AB and Scottish specialty pharmaceutical company ProStrakan Group PLC. The agreement involves the drug Rapinyl for breakthrough cancer pain and Orexo covering North America. Under the terms, Prostrakan will commit to upfront and certain regulatory and sales milestone payments.


Related Articles

  • OREXO'S ASTRAL GETS TWO MORE EU MARKET APPROVALS.  // Worldwide Biotech;Apr2009, Vol. 21 Issue 4, p3 

    The article reports on Marketing Authorizations received by Orexo from the regulatory authorities of France and Spain for AbstralTM, a drug used for the treatment of cancer pain. ProStrakan, Orexo's exclusive licensing partner for AbstralTM in Europe and North America is expected to launch the...

  • OREXO SIGNS PACT FOR ABSTRAL IN MIDDLE EAST/AFRICA.  // Worldwide Biotech;Oct2010, Vol. 22 Issue 10, p3 

    The article reports on the signing of a licensing and distribution agreement between Orexo OB and NewBridge Pharmaceuticals which gives NewBridge rights to seek approval for the marketing of Orexo's Abstral in Africa and the Middle East. NewBridge president Joe Henein vouches for the product's...

  • OREXO/KYOWA HAKKO KIRIN DISTRIBUTE KW-2246 FOR CANCER PAIN.  // Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p7 

    The article reports on the joint distribution agreement signed between Kyowa Hakko Kirin Co. Ltd. and pharmaceutical firm Hisamitsu Pharmaceutical Co. Inc. Kyowa will primarily handle the approval process for the product in Japan. Under the terms of the agreement, the two companies will jointly...

  • ProStrakan to launch Abstrai in France.  // PharmaWatch: CNS;Aug2009, Vol. 8 Issue 8, p15 

    The article reports on the plan of ProStrakan Group PLC to introduce Abstral, a cancer pain drug, in France in July 2009. The drug obtained positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency in June 2008. Moreover, the drug was also...

  • Orexo: Abstral(r) Launched and Now Available in the US.  // Biomedical Market Newsletter;5/21/2011, p407 

    The article reports on the launch of Abstral, fast-acting sublingual tablet for cancer pain, by the partner of Orexo AB, ProStrakan Group PLC in the U.S. It mentions that in 2010 the market value for fast-acting fentanyl products have reached 530 million dollars. It notes that Abstral has been...

  • Pain Licensing Update.  // PharmaWatch: CNS;Dec2005, Vol. 4 Issue 12, p17 

    The article presents news briefs related to the pharmaceutical industry. SkyePharma PLC and the Japanese firm Maruho entered into a marketing partnership to develop and commercialize DepoBupivacaine, which is an injectable local anesthetic. King Pharmaceuticals Inc. entered into an agreement...

  • ABSTRAL.  // MPR - Residents' Edition;Spring/Summer2011, Vol. 20 Issue 1, pA.6 

    The article offers brief information on the opioid drug Abstral from ProStrakan Group PLC.

  • New Adcal--D3 Dissolve.  // British Journal of Community Nursing;Feb2008, Vol. 13 Issue 2, p98 

    The article evaluates the Adcal-D3 Dissolve calcium supplement from ProStrakan company.

  • United Kingdom : ProStrakan announces closing of ARCHIMEDES leverage.  // TendersInfo News;8/9/2014, p1 

    The article reports on the announcement of pharmaceutical company ProStrakan Group PLC for the completion of the buyout for pharmaceutical company Archimedes Pharma Ltd.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics